Fränzel J.B. van Duijnhoven

Wageningen University & Research
Country flagNetherlands

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (22)

Supplementary Figure S5 shows the age-stratified calibration on 5- and 10-year absolute risks based on the PRS-enhanced model stratified by deciles of predicted risk in GERA European ancestry participants.

Year:

2025

Supplementary Figure S4 shows the family-history-stratified calibration on 5- and 10-year absolute risks based on the PRS-enhanced model stratified by deciles of predicted risk in GERA European ancestry participants.

Year:

2025

Background: Currently known associations between common genetic variants and colorectal cancer explain less than half of its heritability of 25%. As alcohol consumption has a J-shape association with colorectal cancer risk, nondrinking and heavy drinking are both risk factors for colorectal cancer. Methods: Individual-level data was pooled from the Colon Cancer Family Registry, Colorectal Transdisciplinary Study, and Genetics and Epidemiology of Colorectal Cancer Consortium to compare nondrinkers (≤1 g/day) and heavy drinkers (>28 g/day) with light-to-moderate drinkers (1–28 g/day) in GxE analyses. To improve power, we implemented joint 2df and 3df tests and a novel two-step method that modifies the weighted hypothesis testing framework. We prioritized putative causal variants by predicting allelic effects using support vector machine models. Results: For nondrinking as compared with light-to-moderate drinking, the hybrid two-step approach identified 13 significant SNPs with pairwise r 2 > 0.9 in the 10q24.2/ COX15 region. When stratified by alcohol intake, the A allele of lead SNP rs2300985 has a dose–response increase in risk of colorectal cancer as compared with the G allele in light-to-moderate drinkers [OR for GA genotype = 1.11; 95% confidence interval (CI), 1.06–1.17; OR for AA genotype = 1.22; 95% CI, 1.14–1.31], but not in nondrinkers or heavy drinkers. Among the correlated candidate SNPs in the 10q24.2/ COX15 region, rs1318920 was predicted to disrupt an HNF4 transcription factor binding motif. Conclusions: Our study suggests that the association with colorectal cancer in 10q24.2/ COX15 observed in genome-wide association study is strongest in nondrinkers. We also identified rs1318920 as the putative causal regulatory variant for the region. Impact: The study identifies multifaceted evidence of a possible functional effect for rs1318920.

Year:

2025

Background: Tobacco smoking is an established risk factor for colorectal cancer. However, genetically defined population subgroups may have increased susceptibility to smoking-related effects on colorectal cancer. Methods: A genome-wide interaction scan was performed including 33,756 colorectal cancer cases and 44,346 controls from three genetic consortia. Results: Evidence of an interaction was observed between smoking status (ever vs. never smokers) and a locus on 3p12.1 (rs9880919, P = 4.58 × 10 −8 ), with higher associated risk in subjects carrying the GG genotype [OR, 1.25; 95% confidence interval (CI), 1.20–1.30] compared with the other genotypes (OR P = 1.72 × 10 −8 ) and 8q24.23 (rs7005722, P = 2.88 × 10 −8 ). Subjects carrying the rs4151657 TT genotype showed higher risk (OR, 1.12; 95% CI, 1.09–1.16) compared with the other genotypes (OR CADM2 (3p12.1) and ATF6B (6p21.33). Conclusions: Our study identified novel genetic loci that may modulate the risk for colorectal cancer of smoking status and intensity, linked to tumor suppression and immune response. Impact: These findings can guide potential prevention treatments.

Year:

2025

Supplementary Figure S2 shows the sex-stratified calibration on 5- and 10-year absolute risks based on the PRS-enhanced model stratified by deciles of predicted risk in GERA European ancestry participants.

Year:

2025

Background: Polygenic risk scores (PRS) which summarize individuals’ genetic risk profile may enhance targeted colorectal cancer screening. A critical step towards clinical implementation is rigorous external validations in large community-based cohorts. This study externally validated a PRS-enhanced colorectal cancer risk model comprising 140 known colorectal cancer loci to provide a comprehensive assessment on prediction performance. Methods: The model was developed using 20,338 individuals and externally validated in a community-based cohort ( n = 85,221). We validated predicted 5-year absolute colorectal cancer risk, including calibration using expected-to-observed case ratios (E/O) and calibration plots, and discriminatory accuracy using time-dependent AUC. The PRS-related improvement in AUC, sensitivity and specificity were assessed in individuals of age 45 to 74 years (screening-eligible age group) and 40 to 49 years with no endoscopy history (younger-age group). Results: In European-ancestral individuals, the predicted 5-year risk calibrated well [E/O = 1.01; 95% confidence interval (CI), 0.91–1.13] and had high discriminatory accuracy (AUC = 0.73; 95% CI, 0.71–0.76). Adding the PRS to a model with age, sex, family and endoscopy history improved the 5-year AUC by 0.06 ( P P = 0.05) in the screening-eligible age and younger-age groups, respectively. Using a risk-threshold of 5-year SEER colorectal cancer incidence rate at age 50 years, adding the PRS had a similar sensitivity but improved the specificity by 11% ( P P = 0.04) with similar specificity. Conclusions: The proposed PRS-enhanced model provides a well-calibrated 5-year colorectal cancer risk prediction and improves discriminatory accuracy in the external cohort. Impact: The proposed model has potential utility in risk-stratified colorectal cancer prevention.

Year:

2025

Supplementary Figure S3 shows the endoscopy-history-stratified calibration on 5- and 10-year absolute risks based on the PRS-enhanced model stratified by deciles of predicted risk in GERA European ancestry participants.

Year:

2025

Background: Fatigue is often reported by colorectal cancer survivors and largely impacts their quality of life. Inflammation has been linked to fatigue mainly in patients with breast cancer. Therefore, we investigated how inflammation is longitudinally associated with fatigue in colorectal cancer survivors, up to 2 years posttreatment. Methods: A total of 257 patients from the ongoing Energy for life after ColoRectal cancer cohort study were included in the analysis. Plasma levels of IL6, IL8, IL10, TNFα, high-sensitivity C-reactive protein (hsCRP), and fatigue were measured at 6 weeks, 6, 12, and 24 months posttreatment. Fatigue was measured through the validated Checklist Individual Strength (CIS; total, 20–140), consisting of four subscales – subjective fatigue (8– 56 ), motivation ( 4–28 ), physical activity ( 3–21 ), and concentration ( 5–35 ), and the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 fatigue subscale (0–100). Linear mixed-models were used to assess the confounder-adjusted longitudinal associations between inflammatory markers and overall fatigue along with the subscales. Results: Mean levels of CIS fatigue decreased from 62.9 at 6 weeks to 53.0 at 24 months. In general, levels of inflammatory markers also decreased over time. No statistically significant longitudinal associations were found between IL6, IL8, IL10, TNFα, and fatigue. Higher levels of hsCRP were associated with more CIS fatigue (β per SD 3.21, 95% confidence interval (CI), 1.42–5.01) and EORTC fatigue (β 2.41, 95% CI, 0.72–4.10). Conclusions: Increased levels of hsCRP are longitudinally associated with more posttreatment fatigue in colorectal cancer survivors. Impact: These findings suggest that low-grade inflammation may play a role in fatigue reported by colorectal cancer survivors up to 2 years posttreatment.

Year:

2025

Supplementary methods show the details of study population, risk model development, calculation of the polygenic risk score, statistical analysis and funding of individual studies in GECCO and CORECT.

Year:

2025

Background Liver fat accumulation has been associated with impaired colorectal cancer prognosis. Associations may differ for colon and rectal cancer due to different disease mechanisms and dissemination patterns. Here, we investigated associations between liver fat and cancer recurrence, recurrence-free survival (RFS), and overall survival (OS) among 1596 individuals with stage I-III colon or rectal cancer. Methods Within a prospective cohort study, we used data from adults recently diagnosed with colon (n = 1080) or rectal (n = 516) cancer. Liver fat was evaluated using routine contrast-enhanced computed tomography (CT)-scans taken at diagnosis. Cox proportional hazards regression analyses adjusted for clinical and lifestyle-related variables were used to obtain hazard ratios (HRs) and 95% confidence intervals (95% CIs). Results During a median follow-up of 6.4 and 8.8 years, 247 (15%) recurrences (12% for colon and 22% for rectal cancer) and 418 (26%) deaths (25% for colon and 29% for rectal cancer) occurred, respectively. More liver fat was associated with an increased recurrence risk (HRT3vsT1 = 1.60, 95% CI = 1.02 to 2.50), worse RFS (HRT3vsT1 = 1.45, 95% CI = 1.05 to 2.00), and OS (HRT3vsT1 = 1.67, 95% CI = 1.20 to 2.33) among individuals with colon cancer. Liver fat was not associated with recurrence (HRT3vsT1 = 0.70, 95% CI = 0.42 to 1.18), RFS (HRT3vsT1 = 0.87, 95% CI = 0.59 to 1.30), or OS (HRT3vsT1 = 1.15, 95% CI = 0.74 to 1.80) among individuals with rectal cancer. Conclusion More liver fat was associated with poor clinical outcomes in patients with stage I-III colon cancer. Further studies are needed to confirm these findings and explore mechanistic routes linking liver fat to colon cancer prognosis.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (74)

Li Hsu

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Polly Newcomb

University of Washington

UNITED STATES
View details

Marc Gunter

International Agency for Research on Cancer

FRANCE
View details

Tabitha Harrison

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Konstantinos K. Tsilidis

-

UNITED KINGDOM
View details

Johannes H W de Wilt

Radboud University Medical Center

NETHERLANDS
View details

Martijn Bours

Associate Professor

University of Maastricht

NETHERLANDS
View details

Victor Moreno

Professor

University of Barcelona

SPAIN
View details

Marina Evangelou

Senior Lecturer in Statistics

Imperial College London

UNITED KINGDOM
View details

Stephanie Breukink

Maastricht University Medical Centre

NETHERLANDS
View details

Susanna Larsson

Professor at Karolinska Institutet

Karolinska Institutet

SWEDEN
View details

Juan Pablo Lewinger

Associate Professor

University of Southern California

UNITED STATES
View details

John Baron

Professor

University of North Carolina

UNITED STATES
View details

David Drew

Assistant Professor of Medicine

Massachusetts General Hospital

UNITED STATES
View details

Bernardus Jacobus Maria Witteman

professor

Wageningen University & Research

NETHERLANDS
View details

Eline H. van Roekel

University of Maastricht

NETHERLANDS
View details

Ulrike Peters

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Jihyoun Jeon

University of Michigan

UNITED STATES
View details

Matthew Devall

Assistant Professor

University of Virginia

UNITED STATES
View details

Sophia Harlid

Umea University

SWEDEN
View details

Eric Kawaguchi

Assistant Professor

University of Southern California

UNITED STATES
View details

Evertine Wesselink

Wageningen University & Research

NETHERLANDS
View details

Julie R Palmer

Boston University School of Medicine

UNITED STATES
View details

Johanna Marianna Geleijnse

Wageningen University & Research

NETHERLANDS
View details

Elizabeth Platz

Professor

Johns Hopkins University

UNITED STATES
View details

Renate Winkels

Wageningen University & Research

NETHERLANDS
View details

Yingye Zheng

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Mariana C. Stern

Professor

University of Southern California

UNITED STATES
View details

Gerard Bryan Gonzales

Associate Professor

Ghent University

BELGIUM
View details

Matty Weijenberg

Professor of Molecular Epidemiology of Cancer

University of Maastricht

NETHERLANDS
View details

Tim Bishop

University of Leeds

UNITED KINGDOM
View details

Elizabeth Hauser

Duke University

UNITED STATES
View details

Richard Hayes

Professor of Population Health and Environmental Medicine

NYU School of Medicine

UNITED STATES
View details

Mingyang Song

Associate Professor

Harvard University

UNITED STATES
View details

Stéphane Bézieau

Université de Nantes

FRANCE
View details

Virginia Díez-Obrero

Vrije Universiteit Amsterdam

NETHERLANDS
View details

Hongmei Nan

Professor

University of Indianapolis

UNITED STATES
View details

Emmanouil Bouras

Research associate

Imperial College London

UNITED KINGDOM
View details

Alicja Wolk

Professor of Nutritional Epidemiology

Karolinska Institutet

SWEDEN
View details

Anna H. Wu

Professor

University of Southern California

UNITED STATES
View details

Robert C. Grant

University Health Network

CANADA
View details

John Potter

Professor

University of Washington

UNITED STATES
View details

Bethany Van Guelpen

Umea University

SWEDEN
View details

Li Li

University of Virginia

UNITED STATES
View details

Iris Lansdorp-Vogelaar

Associate Professor

Erasmus University Medical Center

NETHERLANDS
View details

Dieuwertje Kok

Wageningen University & Research

NETHERLANDS
View details

Andrea Burnett-Hartman

Epidemiologist Program Director

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Andrea Gsur

Medical University of Vienna

AUSTRIA
View details

Loic Le Marchand

Professor

University of Hawaii

UNITED STATES
View details

Edward A. Ruiz-Narváez

Associate Professor

University of Michigan School of Public Health

UNITED STATES
View details

Elom K Aglago

Imperial College London

UNITED KINGDOM
View details

David Conti

Professor

Colorado School of Public Health

UNITED STATES
View details

W. James Gauderman

professor

University of Southern California

UNITED STATES
View details

Vicente Martín-Sánchez

JEFE DE GRUPO

Universidad de León

SPAIN
View details

Paul Pharoah

Professor of Cancer Epidemiology

Cedars-Sinai Medical Center

UNITED STATES
View details

Graham Casey

University of Virginia

UNITED STATES
View details

Catherine Tangen

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Satu Männistö

Finnish Institute for Health and Welfare

FINLAND
View details

Kala Visvanathan

Professor

Johns Hopkins University

UNITED STATES
View details

Jessica Petrick

Boston University

UNITED STATES
View details

Daniel D. Buchanan

Senior Research Fellow

University of Melbourne

AUSTRALIA
View details

Michelle Cotterchio

Professor (status only)

University of Toronto

CANADA
View details

Annika Lindblom

Karolinska Institutet

SWEDEN
View details

Stephen Gruber

Professor

City Of Hope National Medical Center

UNITED STATES
View details

Jochen Hampe

Scientific Speaker

Technische Universität Dresden

GERMANY
View details

Anshul Kundaje

Associate Professor

Stanford University

UNITED STATES
View details

Mark Jenkins

University of Melbourne

AUSTRALIA
View details

Peter T. Campbell

Professor

Albert Einstein College of Medicine

UNITED STATES
View details

Graham Giles

Head of Research

-

AUSTRALIA
View details

Michael Hoffmeister

Professor of Epidemiology, Group leader, Deputy divison head

German Cancer Research Center (DKFZ)

GERMANY
View details

Volker Arndt

Group leader

Deutsches Krebsforschungszentrum

GERMANY
View details

Elizabeth Barry

Associate Professor

Dartmouth College Geisel School of Medicine

UNITED STATES
View details

Pavel Vodička

senior researcher

Charles University

CZECH REPUBLIC
View details

Jennifer Ose

Professorin (W2)

Hochschule Hannover

GERMANY
View details